ListarOtras Comunidades por tema "Inhibidores del Cotransportador de Sodio-Glucosa 2"

Mostrando ítems 1-1 de 1

Evaluation of the effects of sodium–glucose co‐transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR‐Preserved Trial

Anker, Stefan D.; Butler, Javed; Filippatos, Gerasimos; Waheed, Jamal; Salsali, Afshin; Schnee, Janet; Kimura, Karen; Zeller, Cordula; Jyothis, George; Brueckmann, Martina; Zannad, Faiez; Packer, Milton; EMPEROR-Preserved Trial Committees and Investigators (Wiley, 2019-09-16)

Background: The principal biological processes that characterize heart failure with a preserved ejection fraction (HFpEF) are systemic inflammation, epicardial adipose tissue accumulation, coronary microcirculatory ...

Mostrando ítems 1-1 de 1

Buscar en DSpace